Authors | Sample size | Treatment duration | Â | Symptom recurrence rates | Comparator recurrence rate | |||
---|---|---|---|---|---|---|---|---|
 |  |  | 9 months | 12 months | 18 months | 24 months | 36 months |  |
Kane J et al. [24]. | 28 | Not specified | Â | 41% | Â | Â | Â | 0% |
Crow T et al. [26]. | 120 | Not specified | Â | Â | Â | 62% | Â | 46% |
Gitlin M et al. [21]. | 53 | 3 months in remission | Â | 78% | Â | 96% | Â | - |
Wunderink L et al. [25]. | 161 | 6 months in remission | Â | Â | 43% | Â | Â | 21% |
Chen E. et al. [22]. | 178 | 12 months + | Â | 79% | Â | Â | Â | 41% |
Gaebel W. et al. [27]. | 44 | 12 months | Â | 57% | Â | Â | Â | 4% |
Boonstra G. et al. [23]. | 20 | 12 months min remission | 82% | Â | Â | Â | Â | 12% |
Emsley R et al. [10]. | 33 | 24 months | Â | 79% | Â | 94% | 97% | - |